Align Technology reported record second-quarter 2026 revenue of $1.056 billion on July 29, 2026, up 4.3% from the year-ago quarter and 1.5% sequentially, as Clear Aligner volume climbed 7.4% to 691.8 thousand cases and international growth in APAC, EMEA, and Latin America carried the quarter while North America held steady. The headline print was solid but not the day's most consequential news, because on the same date the company announced that it had engaged Elliott Investment Management in a constructive process to add three new independent directors, hired a global consulting firm to run a strategic and operating model review, and raised its 2026 share repurchase commitment to $400 million to $500 million. The equity story for the next twelve months is no longer simply about aligner units; it is about whether a board refresh and an efficiency review can convert a still-lumpy growth profile into a faster, more profitable, and more shareholder-aligned machine.
We read the quarter as evidence that the core clear aligner franchise is sound but the second engine is decelerating. Clear Aligner revenue rose 8.2% to $870.9 million with per-case average selling price up modestly to $1,260, while Imaging Systems and CAD/CAM Services revenue fell 10.8% to $185.3 million as customers shifted toward lower-priced iTero scanners and leasing and rental models that defer upfront revenue. Management frames the scanner trade as a deliberate strategy to grow the installed base and harvest higher-margin treatment revenue later, which we see as a credible but unproven bet that pushes near-term Systems and Services revenue into a 6% to 8% decline for the full year. The market is pricing the company at roughly 17 times forward non-GAAP earnings, a level that assumes the operating-margin line keeps improving roughly 100 basis points a year for 2026 and again for 2027 as management has guided, not that growth re-accelerates sharply.
The single load-bearing risk is that the strategic review, which management says remains ongoing and has not yet produced formal 2027 guidance, translates into aggressive cost cuts and the multi-year scanner-to-treatment revenue shift never recovers the gross margin dollars it gives up. The falsifiable clock is the third-quarter print, when management guides revenue down sequentially to $1.000 billion to $1.020 billion, guides non-GAAP operating margin to approximately 24%, and expects to absorb $20 million to $30 million of gross-margin and $35 million to $50 million of operating-margin restructuring charges. If the Q3 print combines that guidance with visible sequential Clear Aligner volume growth and a non-GAAP operating margin at the high end of the 24% range, the margin-expansion thesis holds; if the scanner mix shift keeps eating total-company growth into 2027, the premium multiple compresses.